On August 19, 2026 Xspray Pharma reported to have invited investors, analysts and media to a conference call following the company’s receipt of a Complete Response Letter, CRL, from the U.S. Food and Drug Administration, FDA, in relation to the company’s New Drug Application, NDA for Dasynoc. The receipt of the CRL was announced in a press release earlier today, 19 August 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Thursday, 20 August 2026
Time: 09:00 CEST
Speaker: Blake Leitch, CEO of Xspray Pharma
Language: English

The conference call will be hosted by Xspray Pharma’s CEO Blake Leitch, who will comment on the content of the CRL, the main remaining questions from the FDA and the company’s view of the next steps in the process. The presentation will be held in English and will conclude with a Q&A session.

If you wish to participate via webcast, please use the following link: View Source

Via the webcast, you are able to ask written questions.

If you wish to ask questions verbally via the teleconference, please register using the following link: View Source

After registration, you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

(Press release, Xspray, AUG 19, 2026, View Source [SID1234670228])